DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $101,658,975 | -46.1% | 409,750 | -47.9% | 1.72% | -38.8% |
| Q2 2023 | $188,736,000 | +1.4% | 786,400 | +6.5% | 2.81% | -6.5% |
| Q1 2023 | $186,171,110 | +1.7% | 738,657 | +7.1% | 3.01% | -10.1% |
| Q4 2022 | $183,116,178 | – | 689,911 | +33.9% | 3.34% | – |
| Q3 2022 | $0 | – | 515,312 | -4.1% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 537,274 | +15.5% | 0.00% | -100.0% |
| Q1 2022 | $136,505,000 | +4.9% | 465,362 | +17.7% | 1.92% | +14.1% |
| Q4 2021 | $130,088,000 | +20.2% | 395,391 | +11.2% | 1.69% | +33.6% |
| Q3 2021 | $108,244,000 | +22.6% | 355,552 | +8.1% | 1.26% | +2.6% |
| Q2 2021 | $88,307,000 | +35.9% | 329,062 | +14.0% | 1.23% | +23.9% |
| Q1 2021 | $64,988,000 | +12.4% | 288,735 | +11.0% | 0.99% | -19.9% |
| Q4 2020 | $57,801,000 | -15.5% | 260,200 | -18.1% | 1.24% | -38.9% |
| Q3 2020 | $68,432,000 | +9.5% | 317,800 | -10.0% | 2.03% | -9.6% |
| Q2 2020 | $62,474,000 | +9.3% | 353,300 | -12.9% | 2.24% | -8.3% |
| Q1 2020 | $57,142,000 | -8.2% | 405,782 | -0.4% | 2.45% | +5.4% |
| Q4 2019 | $62,268,000 | +39.4% | 407,405 | +29.2% | 2.32% | +21.1% |
| Q3 2019 | $44,654,000 | -4.1% | 315,440 | -3.8% | 1.92% | -2.9% |
| Q2 2019 | $46,569,000 | -4.6% | 328,000 | -11.3% | 1.98% | -2.2% |
| Q1 2019 | $48,828,000 | -1.1% | 369,850 | -23.7% | 2.02% | -11.6% |
| Q4 2018 | $49,393,000 | -7.9% | 485,049 | -2.1% | 2.28% | +9.2% |
| Q3 2018 | $53,603,000 | +46.9% | 495,500 | +34.0% | 2.09% | +34.5% |
| Q2 2018 | $36,479,000 | -3.1% | 369,894 | -3.8% | 1.56% | -10.8% |
| Q1 2018 | $37,657,000 | -20.1% | 384,605 | -23.6% | 1.74% | -43.9% |
| Q4 2017 | $47,126,000 | +1.8% | 503,699 | -7.5% | 3.11% | -12.8% |
| Q3 2017 | $46,291,000 | -7.6% | 544,347 | -8.7% | 3.57% | -15.1% |
| Q2 2017 | $50,113,000 | +3.8% | 596,367 | +5.9% | 4.20% | +2.1% |
| Q1 2017 | $48,256,000 | +0.6% | 562,950 | -8.2% | 4.12% | -6.8% |
| Q4 2016 | $47,967,000 | -5.6% | 613,229 | -7.0% | 4.41% | +0.1% |
| Q3 2016 | $50,836,000 | -3.6% | 659,093 | +25.1% | 4.41% | -8.8% |
| Q2 2016 | $52,757,000 | +9.7% | 526,994 | +4.1% | 4.84% | +4.7% |
| Q1 2016 | $48,110,000 | +4.6% | 506,262 | +2.8% | 4.62% | +17.2% |
| Q4 2015 | $45,984,000 | +6.5% | 492,600 | -5.0% | 3.94% | -2.2% |
| Q3 2015 | $43,161,000 | -13.6% | 518,703 | -12.0% | 4.03% | -2.8% |
| Q2 2015 | $49,943,000 | -2.4% | 589,296 | -1.5% | 4.14% | +3.1% |
| Q1 2015 | $51,193,000 | -12.4% | 598,053 | -11.7% | 4.02% | -9.7% |
| Q4 2014 | $58,425,000 | +6.1% | 677,475 | -6.8% | 4.45% | +1.2% |
| Q3 2014 | $55,070,000 | -5.9% | 726,617 | -1.7% | 4.40% | -7.8% |
| Q2 2014 | $58,529,000 | +1.2% | 739,101 | -5.6% | 4.77% | -4.9% |
| Q1 2014 | $57,863,000 | -10.8% | 783,304 | -7.2% | 5.02% | -12.5% |
| Q4 2013 | $64,838,000 | -5.2% | 844,024 | -13.8% | 5.73% | +0.0% |
| Q3 2013 | $68,382,000 | -4.8% | 978,700 | -13.3% | 5.73% | -11.2% |
| Q2 2013 | $71,801,000 | – | 1,128,234 | – | 6.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |